MENU

Helping Establish Best Practices for Managing Hyperkalaemia in CKD and HF Patients in China

Home/Helping Establish Best Practices for Managing Hyperkalaemia in CKD and HF Patients in China

Case Study:

Helping Establish Best Practices for Managing Hyperkalaemia in CKD and HF Patients in China

 

The Client

Our client is a world leader in cardiovascular, renal and metabolism (CVRM) advances, supplying treatments globally for various conditions.

 

Background

We identified, using literature review variation in clinical practice in China for managing hyperkalaemia (HK) and the use of renin-angiotensin-aldosterone system inhibitors (RAASi) in patients with chronic kidney disease (CKD) and heart failure (HF).

 

Opportunity

To establish a multi-specialty consensus on the optimal use of RAASi and the management of HK in patients with CKD and HF across China, to support standardisation of approach.

 

Approach

Triducive designed a Delphi consensus to engage cardiologists and nephrologists across China to discuss HK management challenges

 

Our process

Step 1: A steering group of cardiology and nephrology experts identified key challenges in HK management and created 41 statements reflecting ideal practices. These statements formed the basis of a consensus questionnaire.

Step 2: A structured online survey was developed and disseminated to an extended panel of cardiologists and nephrologists across 21 provinces in China. The online survey tested the strength of agreement that existed in relation to the statements developed by the steering group.

Step 3: A subsequent facilitated review of the full dataset by the steering group led to the development of a core set of recommendations that reflected the results achieved.

Step 4: A manuscript capable of peer-reviewed publication was developed and authored by the steering group. Triducive supported submission to the Chinese Medical Science Journal.

 

Outcomes

  • 150 responses achieved with an even split between cardiologists and nephrologists
  • 12 Recommendations which informs the best practice for the management of HK and the use of renin-angiotensin-aldosterone system inhibitors (RAASi) in patients with chronic kidney disease  and heart failure
  • Published in the Chinese Medical Sciences Journal in June 2024
  • Provided a strong platform to support standardisation of best practice for the management of HK and use of RAASi in patients with chronic kidney CKD and heart failure HF

Testimonials

“This will hopefully transform patient care in the UK”
Consultant Respiratory Physician, UK
“I would like to express my deep gratitute for your team’s wonderful achievements”
Professor in Cardiovascular Immunology, South Korea
“They understand the scope of the work and what we are trying to achieve with what we're doing”
Professor of Pulmonary Medicine, Canada
“In my experience, you have done the most outstanding work”
Project Manager, Global Healthcare Company, Japan
“There is now so much weight of opinion that payers don’t have any reason to say 'no'”
Brand Director, Global Pharma Company, EU
“This will add to the evidence base that will inform future practice across the the EU”
Cardiothoracic Surgeon, Italy
“A great support to transform future surgery across the EU”
Chair, ETST
“This now provides clear focus in an area that has been confused for a long time”
Microbiologist, Germany
“We remember how unusually excellent you were in this project”
Global Medical Affairs Director, Global Pharma Company, UK
“A great piece of work”
Patient Organisation Leader
“They’ve managed to facilitate a publication in a really high impact journal that's gonna make a difference to the management of patients, not just for clinicians like me in the UK but also around the world”  
Professor of Renal Medicine, UK
“What a fantastic job you have all done”
Haematologist, UK

Sign up to our Newsletter